ZBeats Receives FDA Clearance for ZBPro Diagnostic v2.0

Boston, Massachusetts, U.S., September 18, 2026

ZBeats Expands Long-Term ECG Analysis

The newly cleared ZBPro Diagnostic v2.0 is designed to analyze extended ECG recordings collected over periods of up to 14 consecutive days. Longer monitoring periods can provide clinicians with more cardiac rhythm information than a short conventional ECG performed during a single clinical visit. Intermittent arrhythmias may not occur during a brief ECG examination, making extended monitoring useful in situations where symptoms are sporadic. Long-duration ECG recording can capture cardiac rhythm data during everyday activities and over different periods of the day, potentially providing physicians with additional information when evaluating suspected rhythm disturbances.

ZBeats said the latest version of ZBPro expands the platform’s diagnostic capabilities while supporting the analysis of prolonged ECG recordings. The software is intended to assist qualified healthcare professionals in reviewing ECG data and identifying potentially relevant cardiac rhythm patterns. The FDA clearance represents a regulatory milestone for the company’s cardiac diagnostic software and supports the use of the updated platform within its cleared intended-use framework. As with other medical software, clinical decisions remain the responsibility of qualified healthcare professionals using the available patient information.

ZBPro Supports Extended Cardiac Monitoring

Extended ECG monitoring is increasingly used in the evaluation of patients who experience symptoms such as intermittent palpitations, dizziness, fainting, or suspected abnormal heart rhythms. Depending on the clinical situation, wearable and ambulatory ECG devices can record cardiac electrical activity for substantially longer periods than a standard resting ECG. The ability to analyze up to 14 days of ECG data can generate a large volume of cardiac information. Software platforms such as ZBPro are therefore designed to help organize and analyze recorded data so that clinically relevant events can be identified for physician review.

ZBeats’ technology focuses on combining ECG data analysis with digital health workflows, supporting the interpretation of prolonged cardiac recordings. The company has developed its platform to help healthcare professionals process ECG information generated through ambulatory monitoring. Longer monitoring can be particularly relevant for paroxysmal arrhythmias, which may occur unpredictably and therefore be difficult to capture during short-duration testing. A 14-day monitoring window provides a substantially larger observation period, although the appropriate monitoring duration depends on the patient’s symptoms, suspected condition, and clinical assessment. The updated ZBPro platform therefore addresses an important aspect of modern cardiac diagnostics: converting large quantities of continuously recorded ECG information into data that can be efficiently reviewed by healthcare professionals.

FDA Clearance Advances ZBeats Cardiac Technology

The FDA clearance of ZBPro Diagnostic v2.0 adds to ZBeats’ medical technology portfolio and demonstrates the company’s continued development of software designed for cardiac monitoring and ECG analysis. Regulatory clearance is an important step for medical device software because it establishes the permitted use of the technology within the United States under its cleared indications. The development comes amid broader growth in digital cardiac monitoring, with wearable and ambulatory technologies increasingly generating longer-duration physiological datasets. ECG monitoring can provide information about heart rhythm that may not be available from conventional short-duration examinations, while software tools can help clinicians manage and interpret increasingly large datasets.

For healthcare providers, the availability of ECG analysis software capable of supporting recordings lasting up to 14 days may provide another option for workflows involving prolonged ambulatory monitoring. The technology is particularly relevant to the broader shift toward more continuous and data-driven cardiac assessment. The FDA clearance does not itself establish that ZBPro v2.0 improves patient outcomes or that longer monitoring is appropriate for every patient. Instead, it represents regulatory authorization for the cleared software technology and its specified use. With ZBPro Diagnostic v2.0, ZBeats is expanding its capabilities in long-duration ECG analysis and strengthening its position in digital cardiac diagnostics. The company’s latest regulatory milestone highlights the continuing evolution of medical software designed to support extended cardiac monitoring, ECG data analysis, and arrhythmia evaluation.

Source: ZBeats press release